Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial Journal Article uri icon
  • AIMS: To assess the impact of baseline characteristics on clinical outcomes in the LixiLan-L trial, a randomized open-label trial designed to evaluate the efficacy and safety of iGlarLixi, a novel fixed-ratio combination of insulin glargine 100 U (iGlar) plus lixisenatide, in comparison with iGlar over 30 weeks in a population of patients with type 2 diabetes mellitus (T2DM) inadequately controlled on a previous regimen of basal insulin alone or in combination with 1 or 2 oral glucose-lowering drugs. MATERIALS AND METHODS: In this exploratory analysis of LixiLan-L (N = 736), efficacy outcomes were assessed within population subgroups derived from the following baseline characteristics: glycated haemoglobin [HbA1c; <8%, >/=8% (<64, >/=64 mmol/mol)]; duration of T2DM (<10, >/=10 years); body mass index (<30, >/=30 kg/m2 ). Furthermore, the incidence of symptomatic hypoglycaemia with plasma glucose

  • Link to Article
    publication date
  • 2017
  • published in
  • Blood
  • Diabetes
  • Drugs and Drug Therapy
  • Randomized Controlled Trials
  • Additional Document Info
  • 19
  • issue
  • 10